With tens of billions of dollars in revenue each year, the largest publicly traded U.S. pharmaceutical companies answer drug-pricing critics by pointing to their hefty investments in research and development. But they answer to some of the most powerful institutional investors, too—and those shareholders reaped rich rewards in 2019.
